Report

COMPARATIVE ANALYSIS OF NATIONAL DRUG POLICIES:
THE THAILAND EXPERIENCE

Study conducted under the auspices of
College of Public Health, Chulalongkorn University
Thailand

as part of the Comparative Analysis of National Drug Policies Project
in collaboration with
Karolinska Institutet, Sweden
Harvard School of Public Health, USA
Action Programme on Essential Drugs, World Health Organization
Comparative Analysis of National Drug Policies:
The Thailand Experience

Project Advisors:
Dr. Chitr Sitthi-amorn, Dean of the College of Public Health, Chulalongkorn University
Dr. Michael Reich, Department of Population and International Health, Harvard School of
Public Health

Research Team
Sauwakon Ratanawijitrasin, Principal Investigator
B.S. (Pharmacy), M.A. (Public Administration), Ph.D. (Public Administration)
Faculty of Pharmaceutical Sciences / College of Public Health, Chulalongkorn
University
Pornpis Silkavute
B.S. (Pharmacy), M.S. (Biotechnology)
Technical Division, Food and Drug Administration, Ministry of Public Health
Pannipa Akanithapichat
B.S. (Pharmacy), M.A. (Public Administration)
Faculty of Pharmaceutical Science, Srinakharinwirot University

With financial support by:
1. World Health Organization (Thailand) / PICT-HSD
2. College of Public Health, Chulalongkorn University
This is the final draft of the report on the Thai country study as part of the Comparative Analysis of National Drug Policies Project to be submitted to the World Health Organization. Additional editorial changes may be required.
CONTENTS

Research Team
Table of Contents

CHAPTER 1: The Project and Policy Context
Introduction 2
   Project Background
   Organization of the Report
   Policy Background
Objectives 5
   The Cross-Country Comparison Project
   The Thai Project
Research Methods and Tools 6
   NDP Indicators
   Political Mapping
   Data Collection

CHAPTER 2: Indicator Study of National Drug Policy
Policy Content 9
Indicator-Based Assessment of NDP 10
Data Collection: Sources and Methods 11
NDP Indicator Results 25
Discussion 40
   What Do the Indicators Show
      Legislation, Regulation, Selection, and Registration
      Procurement and Distribution
      Price
      Use
      Public Health Information
   What Do the Indicators Measure
      General Measurement Issues
      Measurement Issues Related to the Thai Study
Conclusion 46

CHAPTER 3: Policy Process Study: Generic Labeling and Advertising Policy
Introduction 48
Development of the Generic Labeling and Advertising Policy 48
   Agenda Setting 48
      Putting Generic Labeling and Advertising on the Policy Agenda
      GATT/TRIPs Arguments
      Interest Group Positions
Policy Formulation 52
   Formulating the Generic Requirements
   Public Hearing
   Policy Adoption
Implementation 54
   Technical Problems
   Changing the Requirements
   Dealing with Products in the Market after the Deadline
   Real Implementation of Label and Advertisement Change
Post-Nullification Period 59
Political Mapping Analysis 61
   Defining Terms and Assumptions Used in the Political Mapping Analysis
   Political Mapping Reports
   Discussion

APPENDIX
Generic Labeling and Advertising Policy Contents
   Generic Labeling Policy in Brief
   Ministerial Order # 439/2537: Summary of Content
   Generic Advertising Policy in Brief
   Summary of Drug Committee Resolution Regarding Generic Advertising Policy
Generic Labeling and Advertising Policy Chronology
List of Interviewees
References
APPENDIX